US2024034440A1PendingUtilityA1

Compositions and methods for the induction of cd8+ t-cells

78
Assignee: UNIV KEIOPriority: Dec 23, 2016Filed: Mar 10, 2023Published: Feb 1, 2024
Est. expiryDec 23, 2036(~10.4 yrs left)· nominal 20-yr term from priority
Inventors:Kenya HondaTakeshi TanoueMasahira HattoriYutaka Kawakami
B63B 29/04B63B 2029/043C12Q 1/689C12N 1/20A61K 35/74A61K 39/0208A61K 39/116A61K 35/742C12N 15/09A61K 39/0216A61K 39/114A61K 39/39C07K 16/2818A61K 2039/505A61K 2039/521A61K 2039/542A61K 2039/57A61K 2039/572A61K 2039/585A61K 2039/70A61P 31/04A61P 35/00A61K 2039/82A61K 39/39558A61K 38/20A61K 38/2013A61K 38/2086Y02A50/30A61K 2035/11A61K 2035/115A61K 2039/52A61K 31/7036A61K 35/12A61K 39/08A61K 39/3955A61K 9/0053A61K 9/19A23L 33/135A61K 39/29A61K 45/06C07K 16/2827G01N 2500/00A23V 2200/308A61K 2039/5154A23V 2002/00A61K 9/0031A61P 31/12G01N 33/56911A61K 2039/5158A61K 39/21A61K 2300/00
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Claims

exact text as granted — not AI-modified
1 .- 226 . (canceled) 
     
     
         227 . A pharmaceutical composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 95% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, wherein the pharmaceutical composition further comprises a pH sensitive composition comprising one or more enteric polymers. 
     
     
         228 . The pharmaceutical composition of  claim 227 , wherein the composition further comprises an anti-cancer agent. 
     
     
         229 . The pharmaceutical composition of  claim 228 , wherein the anti-cancer agent is an immune checkpoint inhibitor. 
     
     
         230 . The pharmaceutical composition of  claim 229 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor. 
     
     
         231 . The pharmaceutical composition of  claim 229 , wherein the immune checkpoint inhibitor is nivolumab. 
     
     
         232 . The pharmaceutical composition of  claim 229 , wherein the immune checkpoint inhibitor is pembrolizumab. 
     
     
         233 . The pharmaceutical composition of  claim 229 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor. 
     
     
         234 . The pharmaceutical composition of  claim 227 , further comprising a pharmaceutically acceptable excipient. 
     
     
         235 . The pharmaceutical composition of  claim 227 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         236 . The pharmaceutical composition of  claim 227 , wherein the pharmaceutical composition is formulated for delivery to the intestine. 
     
     
         237 . The pharmaceutical composition of  claim 227 , wherein the pharmaceutical composition is formulated for delivery to the colon. 
     
     
         238 . The pharmaceutical composition of  claim 227 , wherein the bacterial strains are in powdered form. 
     
     
         239 . The pharmaceutical composition of  claim 227 , wherein the pharmaceutical composition is in the form of a capsule. 
     
     
         240 . The pharmaceutical composition of  claim 227 , wherein the pharmaceutical composition induces proliferation and/or accumulation of CD8+ T cells.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.